Logo
x

Search

Subscribe Now

idiopathic pulmonary fibrosis

United Therapeutics Reports the First Patient Enrollment in P-III TETON Study of Tyvaso for Idiopathic Pulmonary Fibrosis

United Therapeutics Reports the First Patient Enrollment in P-III TETON Study of Tyvaso for Idiopathic Pulmonary Fibrosis

  • June 4, 2021
Galapagos and Gilead Discontinue the P-III Trials of Ziritaxestat (GLPG1690) for Idiopathic Pulmonary Fibrosis

Galapagos and Gilead Discontinue the P-III Trials of Ziritaxestat (GLPG1690) for Idiopathic Pulmonary Fibrosis

  • February 11, 2021
Galecto's GB0139 Receives the US FDA's and EMA's Orphan Drug Designations for Idiopathic Pulmonary Fibrosis

Galecto's GB0139 Receives the US FDA's and EMA's Orphan Drug Designations for Idiopathic Pulmonary Fibrosis

  • August 28, 2020
AstraZeneca Signs a License Agreement with Redx Pharma for RXC006 to Treat Idiopathic Pulmonary Fibrosis

AstraZeneca Signs a License Agreement with Redx Pharma for RXC006 to Treat Idiopathic Pulmonary Fibrosis

  • August 5, 2020
AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis

AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis

  • April 30, 2019
Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders

Bayer Signs an Exclusive License Agreement with Kyoto University for Pulmonary Disorders

  • February 1, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.